Who are SYD-101 0.03%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ciclopirox NL, Antifungal treatment, Ciclopirox 8%, Topical Antimicrobial/Antifungal Medications, Ticlopidine and itraconazole, POLYGYNAX®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/syd-101-0-03.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

SYD-101 0.03% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SYD-101 0.03% (SYD-101 0.03%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal agent. Area: Dermatology/Infectious Disease.

phase 3 Antifungal agent Dermatology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

SYD-101 0.03% (SYD-101 0.03%) — Sydnexis, Inc.. SYD-101 is a topical antifungal agent that disrupts fungal cell membrane integrity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SYD-101 0.03% TARGET	SYD-101 0.03%	Sydnexis, Inc.	phase 3	Antifungal agent
Ciclopirox NL	Ciclopirox NL	Galderma R&D	marketed	Topical antifungal agent	Fungal cytochrome P450 enzymes (via metal ion chelation)
Antifungal treatment	Antifungal treatment	Hospices Civils de Lyon	marketed	Antifungal agent (class varies by specific drug: azole, polyene, echinocandin, or other)
Ciclopirox 8%	Ciclopirox 8%	MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA	marketed	Topical antifungal agent	Fungal cytochrome P450 enzymes and polyvalent cation-dependent metalloenzymes
Topical Antimicrobial/Antifungal Medications	Topical Antimicrobial/Antifungal Medications	Mylan Inc.	marketed	Topical antimicrobial/antifungal agents (multiple classes)
Ticlopidine and itraconazole	Ticlopidine and itraconazole	Turku University Hospital	marketed	Antiplatelet agent + Antifungal agent	ADP receptor (P2Y12) for ticlopidine; Fungal CYP51 for itraconazole
POLYGYNAX®	POLYGYNAX®	Laboratoire Innotech International	phase 3	Combination antibiotic and antifungal agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal agent class)

Moberg Pharma AB · 1 drug in this class
Padagis LLC · 1 drug in this class
Sydnexis, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SYD-101 0.03% — Competitive Intelligence Brief. https://druglandscape.com/ci/syd-101-0-03. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing